Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Retinitis Pigmentosa (RP), Rod Cone Dyst...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Active hf-tRNS. — Active hf-tRNS: A weak alternating electric current is applied to the head through two electrodes to affect the cortical excitability of the targeted cells in the brain. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).
  • Device: Placebo/sham hf-tRNS — Placebo/sham hf-tRNS: The tRNS machine will be used as in active stimulation, except the electrical current will not be applied. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).

Primary Outcomes

  • Percentage preferred walking speed (PPWS) (The pre-test and post-tests will take roughly 2 hours to complete.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-01
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Waterloo
Collaborators: The Hong Kong Polytechnic University
Principal Investigators:
  • Benjamin Thompson, PhD (PRINCIPAL_INVESTIGATOR) - University of Waterloo
Contact Information
Study Contact:
Benjamin Thompson, PhD
1+5198884567
ben.thompson@uwaterloo.ca
Melanie A Mungalsingh, PhD
melanie.mungalsingh@uwaterloo.ca
Benjamin Thompson, PhD
1+15198884567
ben.thompson@uwaterloo.ca
University of Waterloo, School of Optometry and Vision Science
Interventions
  • Device: Active hf-tRNS. — Active hf-tRNS: A weak alternating electric current is applied to the head through two electrodes to affect the cortical excitability of the targeted cells in the brain. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).
  • Device: Placebo/sham hf-tRNS — Placebo/sham hf-tRNS: The tRNS machine will be used as in active stimulation, except the electrical current will not be applied. Stimulation instrument: neuroConn DC Stimulator Plus 2019 (Direct current stimulator Model number 0021, power: 1.2 W, charger: 2.9 V (maximum 160 mA)) (neurocaregroup.com), or neuroConn DC Stimulator MC 2016 (Multi-channel stimulator Model number 0028, power: 24 W, rating: 12 V (maximum 2 A)) (neurocaregroup.com).
Study Locations (1 sites)
University of Waterloo, School of Optometry and Vision Science, Waterloo, Ontario N2L 3G1 Canada
Eligibility Criteria
Inclusion Criteria: * Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling. * Have binocular visual acuity or best corrected binocular visual acuity no worse than 6/12 or 20/40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance. * Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent. * Have read and fully comprehends the information in the consent letter. * Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule. Exclusion Criteria: * Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study. * Have been diagnosed with dementia or self-reported dementia with no formal diagnosis. * Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis. * Have been diagnosed with physical or motor impairments resulting in walking and/or balancing issues or self-reported physical or motor impairments resulting in walking and/or balancing issues with no formal diagnosis. * Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and/or mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and/or mobility with no formal diagnosis. * Are unable to follow the researcher's instructions. * Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study. * Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and/or their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable. * Have severe hearing impairment. * Are pregnant or trying to get pregnant. * Fit any of the typical contraindicators for brain stimulation. See contraindicator section below. For all participants the contraindications for brain stimulation are: * Diagnosed with epilepsy or have previously experienced an epileptic seizure. * Implanted medication pump or implanted electronic device, including defibrillator or pacemaker. * Any metal implants in the head (excluding tooth fillings). * Active electric implants anywhere in the body (especially the head region). * On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia. * Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face. * Recurring headaches. * Previous head injury or skull fracture or head/brain surgery. * Heart disease, neurological condition, or a history of cardiac or neurological surgery. * Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.
Conditions Pulmonary Hypertension, Pulmonary Hypert...
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD. Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Pioglitazone 30mg — Study participants will take Pioglitazone 30 mg PO daily
  • Drug: Placebo — Study participants will take a placebo PO daily
  • Diagnostic Test: Labs — Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).

Primary Outcomes

  • Change in Mitochondrial metabolism parameters: Spare respiratory capacity (Day 1, Day 28, Day 70)
  • Change in Mitochondrial metabolism parameters: Maximal respiration (Day 1, Day 28, Day 70)
  • Change in Mitochondrial metabolism parameters: Basal respiration (Day 1, Day 28, Day 70)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-17
Completion: 2028-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Aaron Trammell (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Aaron Trammell, MD, MSc
404-712-8204
awtramm@emory.edu
Jane Gillespie, RN
404-712-8204
jegille@emory.edu
Jane Gillespie, RN
404-712-8204
jegille@emory.edu
Emory Healthcare System
Interventions
  • Drug: Pioglitazone 30mg — Study participants will take Pioglitazone 30 mg PO daily
  • Drug: Placebo — Study participants will take a placebo PO daily
  • Diagnostic Test: Labs — Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
Study Locations (1 sites)
Emory Healthcare System, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * Provision of a signed and dated informed consent form * Stated willingness to comply with all study procedures for the duration of the study * Confirmed to have pulmonary hypertension (PH) due to chronic lung disease at screening * Pulmonary hypertension is defined based on meeting all three of the following measured at rest during the RHC: * Mean pulmonary artery pressure \>20 mmHg * Pulmonary artery wedge pressure ≤15 mmHg * Pulmonary vascular resistance \> 2 Wood units * Pulmonary hypertension is classified in Group 3: PH associated with lung diseases and/or hypoxia * Medications approved for the treatment of pulmonary hypertension must be at a stable dose for at least 30 days * Ability to take oral medication and be willing to adhere to the study intervention regimen * For females of reproductive potential: agreement to use highly effective contraception during study participation and for an additional 4 weeks after the end of study participation. * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner * Agreement to adhere to Lifestyle Considerations (below) throughout the study duration o During this study, participants are asked to arrive in the clinic for study visits in the fasting state. Specifically, participants should abstain from any caloric intake for 6 hours before arrival for the study visit. Exclusion Criteria: * Diabetes mellitus (type 1 or type 2), present within the preceding 1 year * Personal history of symptomatic hypoglycemia within 90 days preceding enrollment * Personal outpatient use of pioglitazone, rosiglitazone, metformin, insulin, or other medications for the indication of diabetes within 90 days preceding enrollment * History of left ventricular failure (systolic or diastolic) * Pulmonary hypertension due to Group 2 PH (PH due to left heart disease) * History of prior or active bladder cancer * Thrombocytopenia (diagnosis or known platelet count ≤120) within 90 days preceding enrollment * Platelet count ≤120 during screening or on the day of enrollment hypertension due to chronic lung disease * Cystic fibrosis * Pregnancy or lactation * Current tobacco use * Known allergic reaction to components of the study medication (pioglitazone) * Treatment with another investigational drug within 30 days
Conditions Cardiovascular (CV) Risk, Preeclampsia (...
Phase Not Applicable
Enrollment 1260
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention. The goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Hypertension (3-6 years after index pregnancy)
  • Abnormal cardiac function (3-6 years after index pregnancy)
  • Biochemical cardiac markers (3-6 years after index pregnancy)
  • Coronary artery disease (3-6 years after index pregnancy)
  • Other cardiovascular major events (3-6 years after index pregnancy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-08-28
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 1260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators: Hospital Sant Joan de Deu, Barcelona Institute for Global Health
Principal Investigators:
  • Elisa Llurba, PhD (PRINCIPAL_INVESTIGATOR) - Hospital de la Sant Creu i Sant Pau
Contact Information
Study Contact:
Elisa Llurba Olivé, PhD
+34 935534078
ellurba@santpau.cat
Pablo García Manau, PhD
+34 627813346
pgarciama@santpau.cat
Pablo García Manau, PhD
+34 627813346
pgarciama@santpau.cat
Hospital de la Santa Creu i de Sant Pau
Interventions
N/A
Study Locations (1 sites)
Hospital de la Santa Creu i de Sant Pau, Barcelona, 08025 Spain
Eligibility Criteria
Inclusion Criteria: * Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1/PlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16/00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19/00702) cohort studies * Who have delivered within the previous 3-6 years. * Give written consent when invited to participate in this study protocol. Exclusion Criteria: * Unwillingness to participate in this study * Probability of loss to follow-up.
Conditions Pregnancy Related
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The single nucleus RNA-seq approach allows the placental transcriptome to be analyzed from nuclei, thus preserving the integrity of placental syncytium. This approach is feasible on small fragments of villi and offers for the first time the possibility to consider the characterization of gene expression within the structural unit of the human placenta during pregnancy (at the 1st trimester and childbirth)

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Non applicable — Placental transcriptomic analysis

Primary Outcomes

  • Analysis of the cellular transcriptomic trajectory of the human placenta (Day 0)
  • Analysis of the cellular transcriptomic trajectory of the human placenta (At childbirth)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-25
Completion: 2029-02
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France, URC-CIC Paris Descartes Necker Cochin
Principal Investigators:
  • Céline MÉHATS, PHD (STUDY_DIRECTOR) - Institut National de la Santé Et de la Recherche Médicale, France
  • Hélène COLLINOT, MD (PRINCIPAL_INVESTIGATOR) - APHP
Contact Information
Study Contact:
Vassilis TSATSARIS, MD PHD
00331 58 41 38 71
vassilis.tsatsaris@aphp.fr
Marie BENHAMMANI-GODARD
0033158411190
marie.godard@aphp.fr
Hélène COLLINOT, MD
0033 1 58 41 38 19
Maternité Port-Royal, Cochin hospital
Interventions
  • Other: Non applicable — Placental transcriptomic analysis
Study Locations (1 sites)
Maternité Port-Royal, Cochin hospital, Paris, IDF 75014 France
Eligibility Criteria
Inclusion Criteria: * Age 18 to 50 * Progressive monofoetal pregnancy between 11 and 15 weeks of amenorrhea * Patient with prenatal medical indication and requesting chorionic villus biopsy with cytogenetic analysis or molecular genetics * Patient scheduled for delivery at Port-Royal Maternity Hospital Exclusion Criteria: * Minor patient * Multiple pregnancy * Patient's objection * Without health insurance * Patient under guardianship or curatorship
Conditions Hypertension (Without Type 2 Diabetes Me...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Wild Blueberry — Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
  • Dietary Supplement: Placebo — Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks

Primary Outcomes

  • Ambulatory Blood Pressure (Baseline, 4 weeks, and 8 weeks)
  • Pulse Wave Velocity (Baseline, 4 weeks, and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-17
Completion: 2027-01-01
Eligibility
Age: 45 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Georgia State University
Principal Investigators:
  • Rafaela G Feresin, PhD (PRINCIPAL_INVESTIGATOR) - Georgia State University
Contact Information
Study Contact:
Rafaela G Feresin, PhD
404-413-1233
berries@gsu.edu
Rafaela Feresin, PhD
404-413-1233
berries@gsu.edu
Georgia State University
Rafaela G Feresin, PhD
Georgia State University
Interventions
  • Dietary Supplement: Wild Blueberry — Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
  • Dietary Supplement: Placebo — Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
Study Locations (1 sites)
Georgia State University, Atlanta, Georgia 30303 United States
Eligibility Criteria
Inclusion Criteria: * Individuals 45-65 years of age * Diagnosis of elevated blood pressure or stage 1 hypertension (systolic blood pressure = 120-139 mmHg and/or diastolic blood pressure = 80-89 mmHg) for at least 6 months * BMI 25-35 kg/m2 via anthropometric measurements. * Ability to give consent Exclusion Criteria: * Allergies to berries * Use of one hypertensive drug for less than three months * Use of more than one anti-hypertensive or statin drug, insulin, antibiotics, and anti-inflammatory drugs, active cancer, gastrointestinal, renal, cardiovascular, thyroid, and neurological disorders or severe head injury * Smoking * Alcohol consumption (\>2 drinks/day) * Consuming antioxidant, probiotic, and prebiotic supplements * Pregnant or lactating * Participating in a weight loss program
Conditions Preeclampsia Postpartum
Phase PHASE2
Enrollment 86
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Aspirin 81Mg Ec Tab — Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.

Primary Outcomes

  • Reduction in sFlt-1 (1 week postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-07-26
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MemorialCare Health System
Collaborators: University of California, Irvine
Principal Investigators:
  • Megan C Oakes, MD MSCI (PRINCIPAL_INVESTIGATOR) - Miller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center
Contact Information
Study Contact:
Megan C Oakes, MD MSCI
562-997-8510
moakes2@memorialcare.org
Ashten B Waks, MD MSPH
562-997-8510
awaks@memorialcare.org
Megan Oakes, MD
562-997-8510
moakes2@memorialcare.org
Miller Children's and Women's Hospital, Long Beach/MemorialCare Long Beach
Interventions
  • Drug: Aspirin 81Mg Ec Tab — Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Study Locations (1 sites)
Miller Children's and Women's Hospital, Long Beach/MemorialCare Long Beach, Long Beach, California 90740 United States
Eligibility Criteria
Inclusion Criteria: * Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria. * Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic. Exclusion Criteria: * Patient age \<18 years old * Non-English or Non-Spanish speaking * Chronic hypertension diagnosed before 20 weeks' gestation * Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction) * Aspirin prescribed postpartum for any other medical condition * Bleeding disorder * Breastfeeding an infant with thrombocytopenia
Conditions Hypertension
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

High blood pressure is a powerful risk factor for heart disease. Black women are more likely to have high blood pressure than white women or Hispanic women. Even when they are aware they have high blood pressure, many people struggle to keep their blood pressure controlled. Research shows a connection between life stress and high blood pressure and heart disease outcomes. Mindfulness training programs can help people regulate their emotions and cope with stress. Research shows that mindfulness programs can also lower blood pressure. This study will compare two programs: MIND-BP, a Zoom-based mindfulness training group; and BOOST, a Zoom-based support group. The aims of the study are to test if the MIND-BP program leads to greater reductions in blood pressure, stress and depressive symptoms than the BOOST program in Black women with high blood pressure who are participating in the Jackson Heart Study. The primary outcome measure is 6-month change in systolic blood pressure. The secondary outcome measures are 6-month changes in perceived stress and depressive symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: MIND-BP — 8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
  • Behavioral: BOOST — The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.

Primary Outcomes

  • Change in Systolic Blood Pressure (Baseline, Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-18
Completion: 2027-05-30
Eligibility
Age: 18 Years – 99 Years
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Tanya Spruill, PhD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Tanya Spruill, PhD
646-923-0626
Tanya.spruill@nyulangone.org
April P. Carson, PhD
University of Mississippi Medical Center
Interventions
  • Behavioral: MIND-BP — 8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
  • Behavioral: BOOST — The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
Study Locations (1 sites)
University of Mississippi Medical Center, Jackson, Mississippi 39216 United States
Eligibility Criteria
Inclusion Criteria: * Female participant in Jackson Heart Study * Willing to be randomized and comply with all aspects of protocol * Willing to be audio-recorded during group sessions. Exclusion Criteria: * Positive cognitive screen (MMSE \<19) * Severe depressive symptoms (CES-D ≥16) * Pregnant or planning to become pregnant in the next 6 months * Current participation in another trial * Arm circumference \>45 cm and \<22 cm
Conditions Stroke, Hypertension, Home Blood Pressur...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The investigators want to improve care for people who have had a stroke. High blood pressure is the leading cause for having a second stroke and can lead to poor brain health. The goal of this study is to compare two new ways of lowering blood pressure. The first way is to help people check their blood pressure at home. The second way is to bring people together and learn about blood pressure in a group setting. The study team thinks that using both methods together will make it easier to lower blood pressure after a stroke. The study team needs this study to test these two methods together in people who have had a stroke. The investigators believe this is an important study because having high blood pressure makes having another stroke very likely. Therefore, the investigators want to lower blood pressure in people with strokes to keep their brains as healthy as possible and to help with stroke recovery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Group medical visits and home blood pressure monitoring — This arm will receive instructions for home blood pressure monitoring but also be enrolled in group medical visits.

Primary Outcomes

  • Systolic Blood Pressure (three months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-22
Completion: 2028-04-30
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: American Heart Association
Contact Information
Study Contact:
Nirupama Yechoor, MD, MSc
857-282-5184
nyechoor@mgh.harvard.edu
Nirupama Yechoor, MD, MSC
8572825184
nyechoor@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Behavioral: Group medical visits and home blood pressure monitoring — This arm will receive instructions for home blood pressure monitoring but also be enrolled in group medical visits.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Incident, mild to moderate, ischemic or hemorrhagic stroke (NIHSS≤15, ICH score≤3) * history or new diagnosis of hypertension * ability to read and speak English * internet access * established primary care physician at MGH Exclusion Criteria: * severe stroke (NIHSS\>15, ICH score\>3) * discharge location to inpatient rehabilitation or skilled nursing facility * dementia * subjects with moderate to severe aphasia without a caregiver to consent on their behalf
Conditions Open Angle Glaucoma, Pseudoexfoliation G...
Phase NA
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to perform trabeculopuncture a test to determine the distal outflow tract function to predict the success of ab interno trabeculectomy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Trabeculopuncture — Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.

Primary Outcomes

  • IOP (before and two hours after trabeculopuncture, one and four weeks postoperatively (after ab interno trabeculectomy), and three months postoperatively)
  • Outflow facility (before and two hours after trabeculopuncture, one and four weeks postoperatively (after ab interno trabeculectomy), and three months postoperatively)
  • Surgical success (at month three)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-13
Completion: 2026-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wuerzburg University Hospital
Principal Investigators:
  • Daniel Kampik, MD, PhD (PRINCIPAL_INVESTIGATOR) - Department of Ophthalmology University Hospital Würzburg
Contact Information
Study Contact:
Raoul Verma-Fuehring, MD
+49 93120120662
vermafuehr_R@ukw.de
Raoul Verma-Führing, MD
0049 93120120662
vermafuehr_R@ukw.de
Uniklinikum Würzburg
Interventions
  • Diagnostic Test: Trabeculopuncture — Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
Study Locations (1 sites)
Uniklinikum Würzburg, Würzburg, Bavaria 97080 Germany
Eligibility Criteria
Inclusion Criteria: * individuals ≥ 18 years of age * clinical diagnosis of: primary open angle glaucoma, pigmentary glaucoma, or pseudoexfoliation glaucoma * uncontrolled intraocular pressure (IOP) with maximally tolerated medical therapy * progressive thinning of retinal nerve fiber layer assessed by Spectral domain optical coherence tomography (p \< 0.05) * progression of visual field defects * visually significant cataract and indication to reduce IOP or glaucoma medication burden Exclusion Criteria: * clinical diagnosis of neovascular glaucoma, angle-closure glaucoma, uveitic glaucoma, neovascular glaucoma * prior glaucoma surgery * preexisting conditions affecting the episcleral venous pressure including Grave's ophthalmopathy, Sturge-Weber syndrome, Arteriovenous fistulas (carotid-cavernous fistula)
Conditions Cirrhosis, Esophageal Varices
Phase PHASE4
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether carvedilol plus endoscopic variceal ligation (EVL) is more effective for the primary prevention of esophageal variceal bleeding than carvedilol alone in carvedilol non-responders. It will also learn about the safety of carvedilol combined with EVL in patients with cirrhosis. The main questions it aims to answer are: Whether carvedilol plus EVL is more effective than carvedilol alone in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol. What medical problems do participants have when taking carvedilol or taking carvedilol combined with undergoing EVL? Researchers will compare the efficacy and safety of carvedilol with or without EVL in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol. Participants will: Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol, or Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable). Visit the clinic once every 2-3 months for checkups and tests. Keep a diary of their vital signs (SBP, DBP, and HR) as well as symptoms.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Carvedilol plus endoscopic variceal ligation — Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
  • Drug: Carvedilol alone — Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).

Primary Outcomes

  • Esophageal variceal bleeding (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-01-06
Completion: 2030-10
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taipei Veterans General Hospital, Taiwan
Contact Information
Study Contact:
Tsung-Chieh Yang, MD
886-2-28712121
tcyang@vghtpe.gov.tw
Ming-Chih Hou, MD
886-2-28712121
mchou@vghtpe.gov.tw
Tsung-Chieh Yang, MD
886-2-28712121
tcyang@vghtpe.gov.tw
Taipei Veterans General Hospital
Interventions
  • Other: Carvedilol plus endoscopic variceal ligation — Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
  • Drug: Carvedilol alone — Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
Study Locations (1 sites)
Taipei Veterans General Hospital, Taipei, 11217 Taiwan
Eligibility Criteria
Inclusion Criteria: \- Cirrhotic patients with esophageal varices who, after carvedilol treatment, continue to experience variceal enlargement or develop new red color signs. Exclusion Criteria: * Age under 18 or over 90 years. * History of esophageal variceal bleeding. * Previous treatment for esophageal varices, including endoscopic variceal ligation, endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt, or surgery. * Contraindications to non-selective beta-blockers, including severe atrioventricular block, chronic obstructive pulmonary disease (COPD), asthma, uncontrolled diabetes mellitus, or severe peripheral artery disease. * Presence of end-stage organ diseases, including hepatocellular carcinoma or other terminal cancers, heart failure, or renal failure. * Pregnant women. * Refusal to participate in the study.
Conditions Arterial Hypertension, Resistant Hyperte...
Phase EARLY_PHASE1
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Beetroot extract — Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
  • Dietary Supplement: Placebo — The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.

Primary Outcomes

  • Assessment of blood pressure evolution (60 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-11-01
Completion: 2026-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Cardiology, Laranjeiras, Brazil
Contact Information
Study Contact:
EDUARDO TIBIRICA, MD, PhD
+55-21-99914-6075
etibi@uol.com.br
Eduardo Tibirica
2125921265
eitib@uol.com.br
National Institute of Cardiology
Interventions
  • Dietary Supplement: Beetroot extract — Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
  • Dietary Supplement: Placebo — The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
Study Locations (1 sites)
National Institute of Cardiology, Rio de Janeiro, 21040-360 Brazil
Eligibility Criteria
Inclusion Criteria: * Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days. Exclusion Criteria: * neoplasms * heart failure * use of medications with nitrate in their formula * patients undergoing renal denervation
Conditions Gestational Diabetes, Hypertensive Disor...
Phase NA
Enrollment 864
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions. Here the investigators propose to conduct a Hybrid Type II Effectiveness-Implementation Randomized Controlled Trial (RCT) to assess the effectiveness and evaluate the implementation of the MOM-HD (Mobile-based Obstetric Monitoring for Hypertension and/or Diabetes) program, a mobile app-based perinatal telemonitoring program, in real-world clinical settings in Nepal. To address the study aims, the investigators will recruit 864 women who are newly diagnosed with HDP and GDM from three metropolitan hospitals and randomly assign them to either (i) MOM-HD + standard care or (ii) standard care alone, from enrolment in pregnancy to 6 weeks postpartum. Primary and secondary clinical outcomes will be assessed at delivery, and at 6 weeks postpartum. The investigators hypothesize that compared to standard care, the use of MOM-HD in addition to standard care will result in lower systolic BP levels, lower incidence rate for the composite adverse perinatal outcome of either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery or labor induction, and lower proportion of days with elevated systolic BP or BG readings between recruitment and 6 weeks postpartum. A convergent mixed-methods approach will be used to assess implementation and maintenance outcomes using the RE-AIM framework (4), and economic sustainability will be assessed by collecting primary cost data.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: MOM-HD — Participants will receive education and training on proper BP and/or BG monitoring and will be provided a BP monitor and/or glucometer with strips. They will be asked to use the MOM-HD mobile app to measure and record daily BP (until 6 weeks postpartum) and, for women with GDM, fasting and 2-hour postprandial BG (until delivery). Readings are automatically uploaded via Bluetooth to a provider portal and reviewed daily by a nurse. Participants will receive automated reminders, instant feedback on readings, and educational materials via the app. They will participate in biweekly tele-visits with a nurse to review readings, discuss symptoms, and receive counseling on lifestyle, diet, and care plans.
  • Other: Standard Care — Pregnant women with HDP and GDM will receive standard antenatal care, which includes more frequent hospital visits (6-8 extra), ultrasound, urine dipstick, BP/BG monitoring with paper record booklets, dietary and physical activity counseling, and OB/GYN follow-up. GDM patients will consult with a dietitian and physical therapist. Postpartum follow-up includes BP/BG testing at 6 weeks.

Primary Outcomes

  • Mean systolic BP from recruitment to delivery (continuous) (Post-treatment (at delivery))
  • Rate of composite adverse perinatal outcome (categorical; either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery, preterm birth ) (Post-treatment (at delivery))
  • Proportion of days with elevated blood pressure (BP) or blood glucose (BG) readings (above clinical target ranges) between recruitment and delivery (continuous) (Post-treatment (at delivery))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-30
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 864 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rutgers, The State University of New Jersey
Collaborators: Dhulikhel Hospital, Institute for Implementation Science and Health
Principal Investigators:
  • Shristi Rawal, PhD (PRINCIPAL_INVESTIGATOR) - Rutgers School of Health Professions
Contact Information
Study Contact:
Shristi Rawal, PhD
+18606908495
shristi.rawal@rutgers.edu
Archana Shrestha, PhD
+9779801002245
archana@kusms.edu.np
Isha Puuri
Nobel Medical College & Teaching Hospital
Interventions
  • Behavioral: MOM-HD — Participants will receive education and training on proper BP and/or BG monitoring and will be provided a BP monitor and/or glucometer with strips. They will be asked to use the MOM-HD mobile app to measure and record daily BP (until 6 weeks postpartum) and, for women with GDM, fasting and 2-hour postprandial BG (until delivery). Readings are automatically uploaded via Bluetooth to a provider portal and reviewed daily by a nurse. Participants will receive automated reminders, instant feedback on readings, and educational materials via the app. They will participate in biweekly tele-visits with a nurse to review readings, discuss symptoms, and receive counseling on lifestyle, diet, and care plans.
  • Other: Standard Care — Pregnant women with HDP and GDM will receive standard antenatal care, which includes more frequent hospital visits (6-8 extra), ultrasound, urine dipstick, BP/BG monitoring with paper record booklets, dietary and physical activity counseling, and OB/GYN follow-up. GDM patients will consult with a dietitian and physical therapist. Postpartum follow-up includes BP/BG testing at 6 weeks.
Study Locations (3 sites)
Nobel Medical College & Teaching Hospital, Biratnagar, Nepal
Dhulikhel Hospital, Dhulikhel, Nepal
Paropakar Maternity and Women's Hospital, Kathmandu, Nepal
Eligibility Criteria
Inclusion Criteria: * Pregnant women receiving antenatal care at RCT site * Diagnosed with one of the following: * Chronic hypertension (sustained systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or on antihypertensive treatment before 20 weeks of gestation) * Gestational hypertension or preeclampsia without severe features (sustained systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg after 20 weeks of gestation) * Gestational diabetes * Age 18 years or older * Access to a smartphone * Gestational age ≤ 34 weeks at enrollment * Able to read and write Exclusion Criteria: * Multifetal pregnancies * Apparent communication difficulties (e.g., hearing, speech, or cognitive impairments), as judged by research assistants * Unable to understand the Nepali language * Severe maternal illness or any condition that precludes active study participation (e.g., preeclampsia with severe features, eclampsia, HELLP syndrome, or other conditions requiring inpatient management) * Declines to provide informed consent